Publications
Detailed Information
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, H. R. | - |
dc.contributor.author | Jung, K. H. | - |
dc.contributor.author | Im, S. -A. | - |
dc.contributor.author | Im, Y. -H. | - |
dc.contributor.author | Kang, S. Y. | - |
dc.contributor.author | Park, K. H. | - |
dc.contributor.author | Lee, S. | - |
dc.contributor.author | Kim, S. -B. | - |
dc.contributor.author | Lee, K. -H. | - |
dc.contributor.author | Ahn, J. S. | - |
dc.contributor.author | Kim, S. I. | - |
dc.contributor.author | Sohn, J. H. | - |
dc.date.accessioned | 2022-03-22T09:11:36Z | - |
dc.date.available | 2022-03-22T09:11:36Z | - |
dc.date.created | 2021-03-22 | - |
dc.date.created | 2021-03-22 | - |
dc.date.created | 2021-03-22 | - |
dc.date.created | 2021-03-22 | - |
dc.date.issued | 2013-06 | - |
dc.identifier.citation | Annals of Oncology, Vol.24 No.6, pp.1485-1490 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 126040 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177236 | - |
dc.description.abstract | Background: This phase II neoadjuvant trial evaluated bevacizumab docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m(2) docetaxel, carboplatin (AUG = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery. | - |
dc.language | 영어 | - |
dc.publisher | Oxford University Press | - |
dc.title | Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mds658 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.identifier.wosid | 000320741500011 | - |
dc.identifier.scopusid | 2-s2.0-84878449611 | - |
dc.citation.endpage | 1490 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 1485 | - |
dc.citation.volume | 24 | - |
dc.identifier.sci | 000320741500011 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Im, S. -A. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CONTAINING THERAPY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EPIRUBICIN | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | bevacizumab | - |
dc.subject.keywordAuthor | carboplatin | - |
dc.subject.keywordAuthor | docetaxel | - |
dc.subject.keywordAuthor | neoadjuvant chemotherapy | - |
dc.subject.keywordAuthor | pathological complete response | - |
dc.subject.keywordAuthor | triple-negative breast cancer | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.